oncology biosimilars

Business news, market intelligence, and global industry analysis.

The Latest

CVS stock slips as Aetna settles Medicare Advantage diagnosis code fraud case for $117.7m

What the Mount Raymond acquisition means for SLAM Exploration Ltd.’s Goodwin project scale (TSXV: SXL)

CVGI surges 54% as CVG names Zoox strategic supplier and issues $700M revenue outlook for 2026

Representative image illustrating rising takeover speculation around Papa John’s International, Inc., as renewed private equity interest and a reported $65-per-share bid from TriArtisan Capital Advisors push the PZZA stock back into focus amid ongoing turnaround efforts.

Papa John’s agrees to explore sale as renewed private equity interest lifts PZZA

Representative image of Dr. Reddy’s biologics facility in Hyderabad, highlighting its growing oncology manufacturing capabilities and biosimilars expansion strategy.

Is Dr. Reddy’s oncology pipeline strong enough to compete with global innovators in 2025 and beyond?

Explore Dr. Reddy’s oncology pipeline, biosimilars approvals, and revenue outlook—can the Hyderabad-based pharma firm compete with global cancer drug innovators?

μFR system
αvβ6-integrin
α4β7 integrin
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures
Zynex

July 15, 2025